Contemporary Issues Surrounding Folic Acid Fortification Initiatives

  • Choi, Jeong-Hwa (School of Environmental and Life Sciences, University of Newcastle) ;
  • Yates, Zoe (Biomedical Sciences and Pharmacy, University of Newcastle) ;
  • Veysey, Martin (Teaching and Research Unit, Central Coast Local Health District) ;
  • Heo, Young-Ran (Department of Food and Nutrition, Chonnam National University) ;
  • Lucock, Mark (School of Environmental and Life Sciences, University of Newcastle)
  • Received : 2014.10.31
  • Accepted : 2014.12.07
  • Published : 2014.12.31


The impact of folate on health and disease, particularly pregnancy complications and congenital malformations, has been extensively studied. Mandatory folic acid fortification therefore has been implemented in multiple countries, resulting in a reduction in the occurrence of neural tube defects. However, emerging evidence suggests increased folate intake may also be associated with unexpected adverse effects. This literature review focuses on contemporary issues of concern, and possible underlying mechanisms as well as giving consideration the future direction of mandatory folic acid fortification. Folate fortification has been associated with the presence of unmetabolized folic acid (PteGlu) in blood, masking of vitamin $B_{12}$ deficiency, increased dosage for anti-cancer medication, photo-catalysis of PteGlu leading to potential genotoxicity, and a role in the pathoaetiology of colorectal cancer. Increased folate intake has also been associated with twin birth and insulin resistance in offspring, and altered epigenetic mechanisms of inheritance. Although limited data exists to elucidate potential mechanisms underlying these issues, elevated blood folate level due to the excess use of PteGlu without consideration of an individual's specific phenotypic traits (e.g. genetic background and undiagnosed disease) may be relevant. Additionally, the accumulation of unmetabolized PteGlu may lead to inhibition of dihydrofolate reductase and other enzymes. Concerns notwithstanding, folic acid fortification has achieved enormous advances in public health. It therefore seems prudent to target and carefully monitor high risk groups, and to conduct well focused further research to better understand and to minimize any risk of mandatory folic acid fortification.


  1. Zhang S, Hunter DJ, Hankinson SE, Giovannucci EL, Rosner BA, Colditz GA, Speizer FE, Willett WC. 1999. A prospective study of folate intake and the risk of breast cancer. JAMA 281: 1632-1637.
  2. Giovannucci EL, Stampfer MJ, Colditz GA, Hunter DJ, Fuchs C, Rosner BA, Speizer FE, Willett WC. 1998. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 129: 517-524.
  3. Kim J, Kim DH, Lee BH, Kang SH, Lee HJ, Lim SY, Suh YK, Ahn YO. 2009. Folate intake and the risk of colorectal cancer in a Korean population. Eur J Clin Nutr 63: 1057-1064.
  4. Yang D, Baumgartner RN, Slattery ML, Wang C, Giuliano AR, Murtaugh MA, Risendal BC, Byers T, Baumgartner KB. 2013. Dietary intake of folate, B-vitamins and methionine and breast cancer risk among Hispanic and non-Hispanic white women. PLoS One 8: e54495.
  5. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, Lucca U. 2004. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 80: 114-122.
  6. D'Anci KE, Rosenberg IH. 2004. Folate and brain function in the elderly. Curr Opin Clin Nutr Metab Care 7: 659-664.
  7. Yates Z, Lucock M. 2003. Interaction between common folate polymorphisms and B-vitamin nutritional status modulates homocysteine and risk for a thrombotic event. Mol Genet Metab 79: 201-213.
  8. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. 1995. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274: 1049-1057.
  9. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. 1995. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332: 286-291.
  10. Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I. 1998. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 97: 437-443.
  11. Moat SJ, Madhavan A, Taylor SY, Payne N, Allen RH, Stabler SP, Goodfellow J, McDowell IF, Lewis MJ, Lang D. 2006. High- but not low-dose folic acid improves endothelial function in coronary artery disease. Eur J Clin Invest 36: 850-859.
  12. van Dijk SC, Smulders YM, Enneman AW, Swart KM, van Wijngaarden JP, Ham AC, van Schoor NM, Dhonukshe-Rutten RA, de Groot LC, Lips P, Uitterlinden AG, Blom HJ, Geleijnse JM, Feskens EJ, van den Meiracker AH, Mattace Raso FU, van der Velde N. 2013. Homocysteine level is associated with aortic stiffness in elderly: cross-sectional results from the B-PROOF study. J Hypertens 31: 952-959.
  13. Xun P, Liu K, Loria CM, Bujnowski D, Shikany JM, Schreiner PJ, Sidney S, He K. 2012. Folate intake and incidence of hypertension among American young adults: a 20-y follow-up study. Am J Clin Nutr 95: 1023-1030.
  14. Cagnacci A, Cannoletta M, Volpe A. 2009. High-dose short-term folate administration modifies ambulatory blood pressure in postmenopausal women. A placebo-controlled study. Eur J Clin Nutr 63: 1266-1268.
  15. Hibbard BM. 1964. The role of folic acid in pregnancy; with particular reference to anaemia, abruption and abortion. J Obstet Gynaecol Br Commonw 71: 529-542.
  16. Chanarin I, Mollin DL, Anderson BB. 1958. Folic acid deficiency and the megaloblastic anaemias. Proc R Soc Med 51: 757-763.
  17. Scholl TO, Hediger ML, Schall JI, Khoo CS, Fischer RL. 1996. Dietary and serum folate: their influence on the outcome of pregnancy. Am J Clin Nutr 63: 520-525.
  18. Rondo PH, Abbott R, Rodrigues LC, Tomkins AM. 1995. Vitamin A, folate, and iron concentrations in cord and maternal blood of intra-uterine growth retarded and appropriate birth weight babies. Eur J Clin Nutr 49: 391-399.
  19. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. 1993. Maternal plasma folate and vitamin $B_{12}$ are independent risk factors for neural tube defects. Q J Med 86: 703-708.
  20. Molloy AM, Mills JL, Kirke PN, Ramsbottom D, McPartlin JM, Burke H, Conley M, Whitehead AS, Weir DG, Scott JM. 1998. Low blood folates in NTD pregnancies are only partly explained by thermolabile 5,10-methylenetetrahydrofolate reductase: low folate status alone may be the critical factor. Am J Med Genet 78: 155-159.<155::AID-AJMG11>3.0.CO;2-M
  21. Czeizel AE, Dudas I. 1992. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 327: 1832-1835.
  22. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, Mulinare J, Zhao P, Wong LY, Gindler J, Hong SX, Correa A. 1999. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention. N Engl J Med 341: 1485-1490.
  23. Medical Research Council Vitamin Study Research Group. 1991. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338: 131-137.
  24. Hertrampf E, Cortes F. 2004. Folic acid fortification of wheat flour: Chile. Nutr Rev 62: S44-S48.
  25. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. 2001. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285: 2981-2986.
  26. Lopez-Camelo JS, Orioli IM, da Graca Dutra M, Nazer-Herrera J, Rivera N, Ojeda ME, Canessa A, Wettig E, Fontannaz AM, Mellado C, Castilla EE. 2005. Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am J Med Genet A 135: 120-125.
  27. Persad VL, Van den Hof MC, Dube JM, Zimmer P. 2002. Incidence of open neural tube defects in Nova Scotia after folic acid fortification. CMAJ 167: 241-245.
  28. Kim YI. 2004. Will mandatory folic acid fortification prevent or promote cancer? Am J Clin Nutr 80: 1123-1128.
  29. Lucock M, Yates Z. 2009. Folic acid fortification: a double-edged sword. Curr Opin Clin Nutr Metab Care 12: 555-564.
  30. Shane B. 2010. Folate chemistry and metabolism. In Folate in Health and Disease. Bailey LB, ed. CRC press, New York, NY, USA. p 2-3.
  31. Offer T, Ames BN, Bailey SW, Sabens EA, Nozawa M, Ayling JE. 2007. 5-Methyltetrahydrofolate inhibits photosensitization reactions and strand breaks in DNA. FASEB J 21: 2101-2107.
  32. Lucock M, Yates Z, Glanvillea T, Leeming R, Simpson N, Daskalakis I. 2003. A critical role for B-vitamin nutrition in human developmental and evolutionary biology. Nutr Res 23: 1463-1475.
  33. Avali EE, Skacel NE, Celikkaya H, Hsieh YC. 2008. Regulation of human dihydrofolate reductase activity and expression. In Folic Acid and Folate. Vol 79, Litwack G, ed. Elsevier, London, UK. Vol 79, p 267-287.
  34. Matthews RG, Haywood BJ. 1979. Inhibition of pig liver methylenetetrahydrofolate reductase by dihydrofolate: some mechanistic and regulatory implications. Biochemistry 18: 4845-4851.
  35. Bailey SW, Ayling JE. 2009. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proc Natl Acad Sci USA 106: 15424-15249.
  36. Liu CT, Hanoian P, French JB, Pringle TH, Hammes-Schiffer S, Benkovic SJ. 2013. Functional significance of evolving protein sequence in dihydrofolate reductase from bacteria to humans. Proc Natl Acad Sci USA 110: 10159-10164.
  37. Johnson WG, Stenroos ES, Spychala JR, Chatkupt S, Ming SX, Buyske S. 2004. New 19 bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR): a risk factor for spina bifida acting in mothers during pregnancy? Am J Med Genet A 124A: 339-345.
  38. Parle-McDermott A, Pangilinan F, Mills JL, Kirke PN, Gibney ER, Troendle J, O'Leary VB, Molloy AM, Conley M, Scott JM, Brody LC. 2007. The 19-bp deletion polymorphism in intron-1 of dihydrofolate reductase (DHFR) may decrease rather than increase risk for spina bifida in the Irish population. Am J Med Genet A 143A: 1174-1180.
  39. van der Linden IJ, Nguyen U, Heil SG, Franke B, Vloet S, Gellekink H, den Heijer M, Blom HJ. 2007. Variation and expression of dihydrofolate reductase (DHFR) in relation to spina bifida. Mol Genet Metab 91: 98-103.
  40. Banka S, Blom HJ, Walter J, Aziz M, Urquhart J, Clouthier CM, Rice GI, de Brouwer AP, Hilton E, Vassallo G, Will A, Smith DE, Smulders YM, Wevers RA, Steinfeld R, Heales S, Crow YJ, Pelletier JN, Jones S, Newman WG. 2011. Identification and characterization of an inborn error of metabolism caused by dihydrofolate reductase deficiency. Am J Hum Genet 88: 216-225.
  41. Cario H, Smith DE, Blom H, Blau N, Bode H, Holzmann K, Pannicke U, Hopfner KP, Rump EM, Ayric Z, Kohne E, Debatin KM, Smulders Y, Schwarz K. 2011. Dihydrofolate reductase deficiency due to a homozygous DHFR mutation causes megaloblastic anemia and cerebral folate deficiency leading to severe neurologic disease. Am J Hum Genet 88: 226-231.
  42. Sadler TW. 1998. Mechanisms of neural tube closure and defects. MRDD Research Reviews 4: 247-253.
  43. Finer LB, Henshaw SK. 2006. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Repro H 38: 90-96.
  44. Scott JM, Kirke PN, Weir DG. 1990. The role of nutrition in neural tube defects. Annu Rev Nutr 10: 277-295.
  45. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, Read AP, Fielding DW. 1980. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1: 339-340.
  46. Smithells RW, Nevin NC, Seller MJ, Sheppard S, Harris R, Read AP, Fielding DW, Walker S, Schorah CJ, Wild J. 1983. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1: 1027-1031.
  47. Mulinare J, Cordero JF, Erickson JD, Berry RJ. 1988. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 260: 3141-3145.
  48. Lawrence MA, Kripalani K. 2013. Profiling national mandatory folic acid fortification policy around the world. In Handbook of Food Fortification and Health. Vol 2, Preedy VR, Srirajaskanthan R, Patel VD, eds. Springer, New York, NY, USA. Vol 2, p 277-289.
  49. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. 1995. Folate levels and neural tube defects. Implications for prevention. JAMA 274: 1698-1702.
  50. Ray JG, Vermeulen MJ, Boss SC, Cole DE. 2002. Increased red cell folate concentrations in women of reproductive age after Canadian folic acid food fortification. Epidemiology 13: 238-240.
  51. Williams LJ, Mai CT, Edmonds LD, Shaw GM, Kirby RS, Hobbs CA, Sever LE, Miller LA, Meaney FJ, Levitt M. 2002. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States. Teratology 66: 33-39.
  52. De Wals P, Tairou F, Van Allen MI, Uh SH, Lowry RB, Sibbald B, Evans JA, Van den Hof MC, Zimmer P, Crowley M, Fernandez B, Lee NS, Niyonsenga T. 2007. Reduction in neural-tube defects after folic acid fortification in Canada. N Engl J Med 357: 135-142.
  53. Williams LJ, Rasmussen SA, Flores A, Kirby RS, Edmonds LD. 2005. Decline in the prevalence of spina bifida and anencephaly by race/ethnicity: 1995-2002. Pediatrics 116: 580-586.
  54. Food and Drug Administration. 1996. Food standards: Amendment of standards of identity for enriched grain products to require addition of folic acid. In Federal Register. Food and Drug Administration. Health and Human Services. Washington, DC, USA. Vol 61, p 8781-8797.
  55. Public Health Agency of Canada. 2003. Folic acid for the primary prevention of neural tube defects. (accessed Oct 2013).
  56. Hertrampf E, Cortes F, Erickson JD, Cayazzo M, Freire W, Bailey LB, Howson C, Kauwell GP, Pfeiffer C. 2003. Consumption of folic acid-fortified bread improves folate status in women of reproductive age in Chile. J Nutr 133: 3166-3169.
  57. Food Standards Australia New Zealand. 2006. Consideration of mandatory fortification with folic acid: final assessment report. au/code/proposals/documents/FAR_P295_Folic_Acid_Fortification_%20Attachs_1_6.pdf (accessed Oct 2013).
  58. Lawrence MA, Chai W, Kara R, Rosenberg IH, Scott J, Tedstone A. 2009. Examination of selected national policies towards mandatory folic acid fortification. Nutr Rev 67: S73-S78.
  59. Wilkinson K. 2012. Bread fortifying with folic acid to be voluntary. (accessed Oct 2013).
  60. Pfeiffer CM, Hughes JP, Lacher DA, Bailey RL, Berry RJ, Zhang M, Yetley EA, Rader JI, Sempos CT, Johnson CL. 2012. Estimation of trends in serum and RBC folate in the U.S. population from pre- to postfortification using assay-adjusted data from the NHANES 1988-2010. J Nutr 142: 886-893.
  61. Dugbaza J, Cunningham J. 2012. Estimates of total dietary folic acid intake in the Australian population following mandatory folic acid fortification of bread. J Nutr Metab 2012: 492353.
  62. Bower C, D'Antoine H, Stanley FJ. 2009. Neural tube defects in Australia: trends in encephaloceles and other neural tube defects before and after promotion of folic acid supplementation and voluntary food fortification. Birth Defects Res A Clin Mol Teratol 85: 269-273.
  63. Abeywardana S, Bower C, Halliday J, Chan A, Sullivan EA. 2010. Prevalence of neural tube defects in Australia prior to mandatory fortification of bread-making flour with folic acid. Aust NZJ Public Health 34: 351-355.
  64. Ray JG, Vermeulen MJ, Boss SC, Cole DE. 2002. Declining rate of folate insufficiency among adults following increased folic acid food fortification in Canada. Can J Public Health 93: 249-253.
  65. Brown RD, Langshaw MR, Uhr EJ, Gibson JN, Joshua DE. 2011. The impact of mandatory fortification of flour with folic acid on the blood folate levels of an Australian population. Med J Aust 194: 65-67.
  66. Smith AD, Kim YI, Refsum H. 2008. Is folic acid good for everyone? Am J Clin Nutr 87: 517-533.
  67. Crider KS, Bailey LB, Berry RJ. 2011. Folic acid food fortification-its history, effect, concerns, and future directions. Nutrients 3: 370-384.
  68. Kelly P, McPartlin J, Goggins M, Weir DG, Scott JM. 1997. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr 65: 1790-1795.
  69. Troen AM, Mitchell B, Sorensen B, Wener MH, Johnston A, Wood B, Selhub J, McTiernan A, Yasui Y, Oral E, Potter JD, Ulrich CM. 2006. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J Nutr 136: 189-194.
  70. Kalmbach RD, Choumenkovitch SF, Troen AM, D'Agostino R, Jacques PF, Selhub J. 2008. Circulating folic acid in plasma: relation to folic acid fortification. Am J Clin Nutr 88: 763-768.
  71. Obeid R, Kasoha M, Kirsch SH, Munz W, Herrmann W. 2010. Concentrations of unmetabolized folic acid and primary folate forms in pregnant women at delivery and in umbilical cord blood. Am J Clin Nutr 92: 1416-1422.
  72. Lucock MD, Wild J, Smithells RW, Hartley R. 1989. In vivo characterization of the absorption and biotransformation of pteroylmonoglutamic acid in man: a model for future studies. Biochem Med Metab Biol 42: 30-42.
  73. Wright AJ, Dainty JR, Finglas PM. 2007. Folic acid metabolism in human subjects revisited: potential implications for proposed mandatory folic acid fortification in the UK. Br J Nutr 98: 667-675.
  74. Tam C, O'Connor D, Koren G. 2012. Circulating unmetabolized folic Acid: relationship to folate status and effect of supplementation. Obstet Gynecol Int 2012: 485179.
  75. Kao TT, Wang KC, Chang WN, Lin CY, Chen BH, Wu HL, Shi GY, Tsai JN, Fu TF. 2008. Characterization and comparative studies of zebrafish and human recombinant dihydrofolate reductases-inhibition by folic acid and polyphenols. Drug Metab Dispos 36: 508-516.
  76. Ashokkumar B, Mohammed ZM, Vaziri ND, Said HM. 2007. Effect of folate oversupplementation on folate uptake by human intestinal and renal epithelial cells. Am J Clin Nutr 86: 159-166.
  77. Junaid MA, Kuizon S, Cardona J, Azher T, Murakami N, Pullarkat RK, Brown WT. 2011. Folic acid supplementation dysregulates gene expression in lymphoblastoid cells-implications in nutrition. Biochem Biophys Res Commun 412: 688-692.
  78. Morris MS, Jacques P. 2010. Folate and neurological function-epidemiological perspective. In Folate in Health and Disease. Bailey LB, ed. CRC press, New York, NY, USA. p 325-346.
  79. Reynolds E. 2006. Vitamin B12, folic acid, and the nervous system. Lancet Neurol 5: 949-960.
  80. Bottiglieri T, Reynolds EH. 2010. Folate and neurological disease-basic mechanisms. In Folate in Health and Disease. Bailey LB, ed. CRC press, New York, NY, USA. p 355-372.
  81. Schmidt RJ, Hansen RL, Hartiala J, Allayee H, Schmidt LC, Tancredi DJ, Tassone F, Hertz-Picciotto I. 2011. Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. Epidemiology 22: 476-485.
  82. James SJ, Melnyk S, Jernigan S, Pavliv O, Trusty T, Lehman S, Seidel L, Gaylor DW, Cleves MA. 2010. A functional polymorphism in the reduced folate carrier gene and DNA hypomethylation in mothers of children with autism. Am J Med Genet B Neuropsychiatr Genet 153B: 1209-1220.
  83. Adams M, Lucock M, Stuart J, Fardell S, Baker K, Ng X. 2007. Preliminary evidence for involvement of the folate gene polymorphism 19 bp deletion-DHFR in occurrence of autism. Neurosci Lett 422: 24-29.
  84. Lucock M, Leeming R. 2013. Autism, seasonality and the environmental perturbation of epigenome related vitamin levels. Med Hypotheses 80: 750-755.
  85. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, Mattson MP. 2002. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22: 1752-1762.
  86. Janssens V, Longin S, Goris J. 2008. PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci 33: 113-121.
  87. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, Fan G, Sun YE. 2003. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302: 890-893.
  88. Cunha C, Angelucci A, D'Antoni A, Dobrossy MD, Dunnett SB, Berardi N, Brambilla R. 2009. Brain-derived neurotrophic factor (BDNF) overexpression in the forebrain results in learning and memory impairments. Neurobiol Dis 33: 358-368.
  89. Troen AM, Chao WH, Crivello NA, D'Anci KE, Shukitt-Hale B, Smith DE, Selhub J, Rosenberg IH. 2008. Cognitive impairment in folate-deficient rats corresponds to depleted brain phosphatidylcholine and is prevented by dietary methionine without lowering plasma homocysteine. J Nutr 138: 2502-2509.
  90. Stahl SM. 2008. L-methylfolate: a vitamin for your monoamines. J Clin Psychiatry 69: 1352-1353.
  91. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. 2000. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry 69: 228-232.
  92. Herrmann W, Obeid R. 2007. Biomarkers of folate and vitamin B(12) status in cerebrospinal fluid. Clin Chem Lab Med 45: 1614-1620.
  93. Woodside JV, Young IS. 2002. Folate, homocysteine, and cardiovascular disease. In Folate and Human Development. Massaro EJ, Rogers JM, eds. Humana Press, Totowa, NJ, USA. p 329-344.
  94. Victor VM, Rocha M, Sola E, Banuls C, Garcia-Malpartida K, Hernandez-Mijares A. 2009. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 15: 2988-3002.
  95. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM. 2001. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 107: 675-683.
  96. Loscalzo J. 1996. The oxidant stress of hyperhomocyst(e) inemia. J Clin Invest 98: 5-7.
  97. Durand P, Lussier-Cacan S, Blache D. 1997. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophagederived tissue factor activity in rats. FASEB J 11: 1157-1168.
  98. Pathansali R, Mangoni AA, Creagh-Brown B, Lan ZC, Ngow GL, Yuan XF, Ouldred EL, Sherwood RA, Swift CG, Jackson SH. 2006. Effects of folic acid supplementation on psychomotor performance and hemorheology in healthy elderly subjects. Arch Gerontol Geriatr 43: 127-137.
  99. Fioravanti M, Ferrario E, Massaia M, Cappa G, Rivolta G, Grossi E, Buckley AE. 1998. Low folate levels in the cognitive decline of elderly patients and the efficacy of folate as a treatment for improving memory deficits. Arch Gerontol Geriatr 26: 1-13.
  100. Godfrey PS, Toone BK, Carney MW, Flynn TG, Bottiglieri T, Laundy M, Chanarin I, Reynolds EH. 1990. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 336: 392-395.
  101. Coppen A, Chaudhry S, Swade C. 1986. Folic acid enhances lithium prophylaxis. J Affect Disord 10: 9-13.
  102. Reynolds EH. 2002. Benefits and risks of folic acid to the nervous system. J Neurol Neurosurg Psychiatry 72: 567-571.
  103. Tremblay E, Cavalheiro E, Ben-Ari Y. 1983. Are convulsant and toxic properties of folates of the kainate type? Eur J Pharmacol 93: 283-286.
  104. Hommes OR, Obbens EA. 1972. The epileptogenic action of Na-folate in the rat. J Neurol Sci 16: 271-281.
  105. Morrell MJ. 2002. Folic acid and epilepsy. Epilepsy Curr 2: 31-34.
  106. Ogawa Y, Kaneko S, Otani K, Fukushima Y. 1991. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 8: 75-78.
  107. Krishnamurthy KB. 2012. Managing epilepsy during pregnancy: assessing risk and optimizing care. Curr Treat Options Neurol 14: 348-355.
  108. Scott JM, Weir DG. 1981. The methyl folate trap. A physiological response in man to prevent methyl group deficiency in kwashiorkor (methionine deficiency) and an explanation for folic-acid induced exacerbation of subacute combined degeneration in pernicious anaemia. Lancet 2: 337-340.
  109. Sunden SL, Renduchintala MS, Park EI, Miklasz SD, Garrow TA. 1997. Betaine-homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene. Arch Biochem Biophys 345: 171-174.
  110. Wills L, Clutterbuck PW, Evans BD. 1937. A new factor in the production and cure of macrocytic anaemias and its relation to other haemopoietic principles curative in pernicious anaemia. Biochem J 31: 2136-2147.
  111. Selhub J, Morris MS, Jacques PF, Rosenberg IH. 2009. Folate-vitamin B-12 interaction in relation to cognitive impairment, anemia, and biochemical indicators of vitamin B-12 deficiency. Am J Clin Nutr 89: 702S-706S.
  112. Molloy A. 2010. Folate-vitamin B12 interrelationships links to disease risk. In Folate in Health and Disease. Bailey LB, ed. CRC press, New York, NY, USA. p 381-408.
  113. Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. 1991. Neurologic aspects of cobalamin deficiency. Medicine (Baltimore) 70: 229-245.
  114. Morris MC, Evans DA, Bienias JL, Tangney CC, Hebert LE, Scherr PA, Schneider JA. 2005. Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol 62: 641-645.
  115. Moore EM, Ames D, Mander AG, Carne RP, Brodaty H, Woodward MC, Boundy K, Ellis KA, Bush AI, Faux NG, Martins RN, Masters CL, Rowe CC, Szoeke C, Watters DA. 2014. Among vitamin B12 deficient older people, high folate levels are associated with worse cognitive function: combined data from three cohorts. J Alzheimers Dis 39: 661-668.
  116. Nilsson-Ehle H, Landahl S, Lindstedt G, Netterblad L, Stockbruegger R, Westin J, Ahren C. 1989. Low serum cobalamin levels in a population study of 70- and 75-year-old subjects. Gastrointestinal causes and hematological effects. Dig Dis Sci 34: 716-723.
  117. Qi YP, Do AN, Hamner HC, Pfeiffer CM, Berry RJ. 2014. The prevalence of low serum vitamin B-12 status in the absence of anemia or macrocytosis did not increase among older U.S. adults after mandatory folic acid fortification. J Nutr 144: 170-176.
  118. Ray JG, Vermeulen MJ, Langman LJ, Boss SC, Cole DE. 2003. Persistence of vitamin B12 insufficiency among elderly women after folic acid food fortification. Clin Biochem 36: 387-391.
  119. Kim YI. 2007. Folate and colorectal cancer: an evidence-based critical review. Mol Nutr Food Res 51: 267-292.
  120. Bailey LB, Rampersaud GC, Kauwell GP. 2003. Folic acid supplements and fortification affect the risk for neural tube defects, vascular disease and cancer: evolving science. J Nutr 133: 1961S-1968S.
  121. Giovannucci E. 2002. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 132: 2350S-2355S.
  122. Zschabitz S, Cheng TY, Neuhouser ML, Zheng Y, Ray RM, Miller JW, Song X, Maneval DR, Beresford SA, Lane D, Shikany JM, Ulrich CM. 2013. B vitamin intakes and incidence of colorectal cancer: results from the Women's Health Initiative Observational Study cohort. Am J Clin Nutr 97: 332-343.
  123. Jaszewski R, Misra S, Tobi M, Ullah N, Naumoff JA, Kucuk O, Levi E, Axelrod BN, Patel BB, Majumdar AP. 2008. Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. World J Gastroenterol 14: 4492-4498.
  124. Porcelli B, Frosi B, Rosi F, Arezzini L, Civitelli S, Tanzini G, Marinello E. 1996. Levels of folic acid in plasma and in red blood cells of colorectal cancer patients. Biomed Pharmacother 50: 303-305.
  125. Kato I, Dnistrian AM, Schwartz M, Toniolo P, Koenig K, Shore RE, Akhmedkhanov A, Zeleniuch-Jacquotte A, Riboli E. 1999. Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. Br J Cancer 79: 1917-1922.
  126. Vollset SE, Clarke R, Lewington S, Ebbing M, Halsey J, Lonn E, Armitage J, Manson JE, Hankey GJ, Spence JD, Galan P, Bonaa KH, Jamison R, Gaziano JM, Guarino P, Baron JA, Logan RF, Giovannucci EL, den Heijer M, Ueland PM, Bennett D, Collins R, Peto R. 2013. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet 381: 1029-1036.
  127. Qin X, Cui Y, Shen L, Sun N, Zhang Y, Li J, Xu X, Wang B, Xu X, Huo Y, Wang X. 2013. Folic acid supplementation and cancer risk: a meta-analysis of randomized controlled trials. Int J Cancer 133: 1033-1041.
  128. Hirsch S, Sanchez H, Albala C, de la Maza MP, Barrera G, Leiva L, Bunout D. 2009. Colon cancer in Chile before and after the start of the flour fortification program with folic acid. Eur J Gastroenterol Hepatol 21: 436-439.
  129. Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G, Rosenberg IH. 2007. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev 16: 1325-1329.
  130. Maserejian NN, Giovannucci E, Rosner B, Joshipura K. 2007. Prospective study of vitamins C, E, and A and carotenoids and risk of oral premalignant lesions in men. Int J Cancer 120: 970-977.
  131. Ibiebele TI, Hughes MC, Pandeya N, Zhao Z, Montgomery G, Hayward N, Green AC, Whiteman DC, Webb PM. 2011. High intake of folate from food sources is associated with reduced risk of esophageal cancer in an Australian population. J Nutr 141: 274-283.
  132. Roswall N, Olsen A, Christensen J, Dragsted LO, Overvad K, Tjonneland A. 2010. Micronutrient intake and risk of colon and rectal cancer in a Danish cohort. Cancer Epidemiol 34: 40-46.
  133. Shpitz B, Bomstein Y, Mekori Y, Cohen R, Kaufman Z, Grankin M, Bernheim J. 1997. Proliferating cell nuclear antigen as a marker of cell kinetics in aberrant crypt foci, hyperplastic polyps, adenomas, and adenocarcinomas of the human colon. Am J Surg 174: 425-430.
  134. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, McKeown-Eyssen G, Summers RW, Rothstein RI, Burke CA, Snover DC, Church TR, Allen JI, Robertson DJ, Beck GJ, Bond JH, Byers T, Mandel JS, Mott LA, Pearson LH, Barry EL, Rees JR, Marcon N, Saibil F, Ueland PM, Greenberg ER. 2007. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 297: 2351-2359.
  135. Kim YI. 2005. Nutritional epigenetics: impact of folate deficiency on DNA methylation and colon cancer susceptibility. J Nutr 135: 2703-2709.
  136. Lee JE, Willett WC, Fuchs CS, Smith-Warner SA, Wu K, Ma J, Giovannucci E. 2011. Folate intake and risk of colorectal cancer and adenoma: modification by time. Am J Clin Nutr 93: 817-825.
  137. Baggott JE, Morgan SL. 2008. Folic acid supplements are good (not bad) for rheumatoid arthritis patients treated with low-dose methotrexate. Am J Clin Nutr 88: 479-480.
  138. Bertino JR. 2009. Cancer research: from folate antagonism to molecular targets. Best Pract Res Clin Haematol 22: 577-582.
  139. Arabelovic S, Sam G, Dallal GE, Jacques PF, Selhub J, Rosenberg IH, Roubenoff R. 2007. Preliminary evidence shows that folic acid fortification of the food supply is associated with higher methotrexate dosing in patients with rheumatoid arthritis. J Am Coll Nutr 26: 453-455.
  140. Assaraf YG. 2007. Molecular basis of antifolate resistance. Cancer Metastasis Rev 26: 153-181.
  141. Hirsch S, Miranda D, Munoz E, Montoya M, Ronco AM, de la Maza MP, Bunout D. 2013. Natural killer cell cytotoxicity is not regulated by folic acid in vitro. Nutrition 29: 772-776.
  142. Dantola ML, Denofrio MP, Zurbano B, Gimenez CS, Ogilby PR, Lorente C, Thomas AH. 2010. Mechanism of photooxidation of folic acid sensitized by unconjugated pterins. Photochem Photobiol Sci 9: 1604-1612.
  143. Serrano MP, Lorente C, Vieyra FE, Borsarelli CD, Thomas AH. 2012. Photosensitizing properties of biopterin and its photoproducts using 2'-deoxyguanosine 5'-monophosphate as an oxidizable target. Phys Chem Chem Phys 14: 11657-11665.
  144. Hirakawa K, Suzuki H, Oikawa S, Kawanishi S. 2003. Sequence-specific DNA damage induced by ultraviolet A-irradiated folic acid via its photolysis product. Arch Biochem Biophys 410: 261-268.
  145. Ito K, Kawanishi S. 1997. Photoinduced hydroxylation of deoxyguanosine in DNA by pterins: sequence specificity and mechanism. Biochemistry 36: 1774-1781.
  146. Yamada H, Arai T, Endo N, Yamashita K, Nonogawa M, Makino K, Fukuda K, Sasada M, Uchiyama T. 2005. Photodynamic effects of a novel pterin derivative on a pancreatic cancer cell line. Biochem Biophys Res Commun 333: 763-767.
  147. Wada S, Tabuchi Y, Kondo T, Cui ZG, Zhao QL, Takasaki I, Salunga TL, Ogawa R, Arai T, Makino K, Furuta I. 2007. Gene expression in enhanced apoptosis of human lymphoma U937 cells treated with the combination of different free radical generators and hyperthermia. Free Radic Res 41: 73-81.
  148. Arai T, Endo N, Yamashita K, Sasada M, Mori H, Ishii H, Hirota K, Makino K, Fukuda K. 2001. 6-Formylpterin, a xanthine oxidase inhibitor, intracellularly generates reactive oxygen species involved in apoptosis and cell proliferation. Free Radic Biol Med 30: 248-259.
  149. Scurachio RS, Skibsted LH, Metzker G, Cardoso DR. 2011. Photodegradation of folate sensitized by riboflavin. Photochem Photobiol 87: 840-845.
  150. Czeizel AE, Metneki J, Dudas I. 1994. Higher rate of multiple births after periconceptional vitamin supplementation. N Engl J Med 330: 1687-1688.
  151. Kallen B. 2004. Use of folic acid supplementation and risk for dizygotic twinning. Early Hum Dev 80: 143-151.
  152. Ericson A, Kallen B, Aberg A. 2001. Use of multivitamins and folic acid in early pregnancy and multiple births in Sweden. Twin Res 4: 63-66.
  153. Nazer HJ, Aguila RA, Cifuentes OL. 2006. The frequency of twin pregnancies increased in a Chilean hospital associated with periconceptional flour folic acid supplementation. Rev Med Chil 134: 48-52.
  154. Signore C, Mills JL, Cox C, Trumble AC. 2005. Effects of folic acid fortification on twin gestation rates. Obstet Gynecol 105: 757-462.
  155. Werler MM, Cragan JD, Wasserman CR, Shaw GM, Erickson JD, Mitchell AA. 1997. Multivitamin supplementation and multiple births. Am J Med Genet 71: 93-96.<93::AID-AJMG17>3.0.CO;2-Q
  156. Waller DK, Tita AT, Annegers JF. 2003. Rates of twinning before and after fortification of foods in the US with folic acid, Texas, 1996 to 1998. Paediatr Perinat Epidemiol 17: 378-383.
  157. Lawrence JM, Watkins ML, Chiu V, Erickson JD, Petitti DB. 2004. Food fortification with folic acid and rate of multiple births, 1994-2000. Birth Defects Res A Clin Mol Teratol 70: 948-952.
  158. Haggarty P, McCallum H, McBain H, Andrews K, Duthie S, McNeill G, Templeton A, Haites N, Campbell D, Bhattacharya S. 2006. Effect of B vitamins and genetics on success of in-vitro fertilisation: prospective cohort study. Lancet 367: 1513-1519.
  159. Martin JA, Park MM. 1999. Trends in twin and triplet births: 1980-97. Natl Vital Stat Rep 47: 1-16.
  160. Yajnik CS, Deshpande SS, Jackson AA, Refsum H, Rao S, Fisher DJ, Bhat DS, Naik SS, Coyaji KJ, Joglekar CV, Joshi N, Lubree HG, Deshpande VU, Rege SS, Fall CH. 2008. Vitamin $B_{12}$ and folate concentrations during pregnancy and insulin resistance in the offspring: the Pune Maternal Nutrition Study. Diabetologia 51: 29-38.
  161. Houghton LA, Yang J, O'Connor DL. 2009. Unmetabolized folic acid and total folate concentrations in breast milk are unaffected by low-dose folate supplements. Am J Clin Nutr 89: 216-220.
  162. Reyes-Engel A, Munoz E, Gaitan MJ, Fabre E, Gallo M, Dieguez JL, Ruiz M, Morell M. 2002. Implications on human fertility of the 677C>T and 1298A>C polymorphisms of the MTHFR gene: consequences of a possible genetic selection. Mol Hum Reprod 8: 952-957.
  163. Haggarty P, Campbell DM, Duthie S, Andrews K, Hoad G, Piyathilake C, Fraser I, McNeill G. 2008. Folic acid use in pregnancy and embryo selection. BJOG 115: 851-856.
  164. Munoz-Moran E, Dieguez-Lucena JL, Fernandez-Arcas N, Peran-Mesa S, Reyes-Engel A. 1998. Genetic selection and folate intake during pregnancy. Lancet 352: 1120-1121.
  165. Suren P, Roth C, Bresnahan M, Haugen M, Hornig M, Hirtz D, Lie KK, Lipkin WI, Magnus P, Reichborn-Kjennerud T, Schjolberg S, Davey Smith G, Oyen AS, Susser E, Stoltenberg C. 2013. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA 309: 570-577.
  166. Schmidt RJ, Tancredi DJ, Ozonoff S, Hansen RL, Hartiala J, Allayee H, Schmidt LC, Tassone F, Hertz-Picciotto I. 2012. Maternal periconceptional folic acid intake and risk of autism spectrum disorders and developmental delay in the CHARGE (CHildhood Autism Risks from Genetics and Environment) case-control study. Am J Clin Nutr 96: 80-89.
  167. Beard CM, Panser LA, Katusic SK. 2011. Is excess folic acid supplementation a risk factor for autism? Med Hypotheses 77: 15-17.
  168. DeSoto MC, Hitlan RT. 2012. Synthetic folic acid supplementation during pregnancy may increase the risk of developing autism. J Pediatr Biochem 2: 251-261.
  169. Leeming RJ, Lucock M. 2009. Autism: is there a folate connection? J Inherit Metab Dis 32: 400-402.
  170. Rogers EJ. 2008. Has enhanced folate status during pregnancy altered natural selection and possibly Autism prevalence? A closer look at a possible link. Med Hypotheses 71: 406-410.
  171. Vasquez K, Kuizon S, Junaid M, Idrissi AE. 2013. The effect of folic acid on GABAA-B1 receptor subunit. Adv Exp Med Biol 775: 101-109.
  172. Adler NE, Boyce WT, Chesney MA, Folkman S, Syme SL. 1993. Socioeconomic inequalities in health. No easy solution. JAMA 269: 3140-3145.
  173. Department of Health and Human Services. 2009. Healthy people 2010: general data issues. (accessed Oct 2013).
  174. Dowd JB, Aiello AE. 2008. Did national folic acid fortification reduce socioeconomic and racial disparities in folate status in the US? Int J Epidemiol 37: 1059-1066.
  175. Yang QH, Carter HK, Mulinare J, Berry RJ, Friedman JM, Erickson JD. 2007. Race-ethnicity differences in folic acid intake in women of childbearing age in the United States after folic acid fortification: findings from the National Health and Nutrition Examination Survey, 2001-2002. Am J Clin Nutr 85: 1409-1416.
  176. Lynch J, Davey Smith G, Harper S, Bainbridge K. 2006. Explaining the social gradient in coronary heart disease: comparing relative and absolute risk approaches. J Epidemiol Community Health 60: 436-441.
  177. Rabovskaja V, Parkinson B, Goodall S. 2013. The cost-effectiveness of mandatory folic acid fortification in Australia. J Nutr 143: 59-66.
  178. Boxmeer JC, Fauser BC, Macklon NS. 2006. Effect of B vitamins and genetics on success of in-vitro fertilisation. Lancet 368: 200.
  179. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H, Friedman JM. 2006. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113: 1335-1343.

Cited by

  1. Plasma folate levels and associated factors in women planning to become pregnant in a population with high prevalence of neural tube defects vol.109, pp.13, 2017,
  2. Clinical, etiological and therapeutic aspects of cerebral folate deficiency vol.15, pp.7, 2015,
  3. Vitamin D Receptor Polymorphisms Relate to Risk of Adenomatous Polyps in a Sex-Specific Manner vol.68, pp.2, 2016,
  4. Food fortification for impact: a data-driven approach vol.94, pp.8, 2016,
  5. Could folic acid influence growth cone motility during the development of neural connectivity? vol.3, pp.1, 2016,
  6. Implications of Applying Minimal Risk Standards in Clinical Research to Information Provision in Prenatal and Pre-conception Care vol.38, pp.10, 2016,
  7. UV-associated decline in systemic folate: implications for human nutrigenetics, health, and evolutionary processes vol.29, pp.2, 2017,
  8. Micronutrients, Essential Fatty Acids and Bone Health in Phenylketonuria vol.70, pp.2, 2017,
  9. Follicular Fluid redox involvement for ovarian follicle growth vol.10, pp.1, 2017,
  10. Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12 levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin vol.39, pp.3, 2016,
  11. Maternal micronutrient consumption periconceptionally and during pregnancy: a prospective cohort study vol.20, pp.02, 2017,
  12. Effect of vitamin B12 and omega-3 fatty acid supplementation on brain neurotrophins and cognition in rats: A multigeneration study vol.128-129, 2016,
  13. B vitamins and pollution, an interesting, emerging, yet incomplete picture of folate and the exposome vol.114, pp.20, 2017,
  14. Homocysteine-reducing B vitamins and ischemic heart disease: a separate-sample Mendelian randomization analysis vol.71, pp.2, 2017,
  15. Vitamin D vol.20, pp.4, 2015,
  16. The Dihydrofolate Reductase 19 bp Polymorphism Is Not Associated with Biomarkers of Folate Status in Healthy Young Adults, Irrespective of Folic Acid Intake vol.145, pp.10, 2015,
  17. Dihydrofolate reductase 19-bp deletion polymorphism modifies the association of folate status with memory in a cross-sectional multi-ethnic study of adults vol.102, pp.5, 2015,
  18. Peripheral neuropathy risk and a transcobalamin polymorphism: connecting the dots between excessive folate intake and disease susceptibility vol.104, pp.6, 2016,
  19. Is High Folic Acid Intake a Risk Factor for Autism?—A Review vol.7, pp.12, 2017,
  20. Formation of folates by microorganisms: towards the biotechnological production of this vitamin vol.102, pp.20, 2018,
  21. Determinants of folic acid supplement use outside national recommendations for pregnant women: results from the Growing Up in New Zealand cohort study vol.21, pp.12, 2018,
  22. Plasma B-vitamin and one-carbon metabolites and risk of breast cancer before and after folic acid fortification in the United States vol.144, pp.8, 2019,